Dr. Abbey Doses First Patient in Phase 1b/2a LOTUS-2 Clinical Trial of Novel Multivalent Fusion Antibody EB-105 for Diabetic Macular Edema
On October 28, 2025, Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, dosed the first patient in the Phase 1b/2a LOTUS-2 clinical trial of novel multivalent fusion antibody (EB-105) for diabetic
read more
Initial Results of Phase Ib LOTUS Clinical Trial on Potential New Diabetic Macular Edema Treatment Released
On June 9, 2025, Eluminex Biosciences Limited, a clinical-stage protein therapeutics company, announced positive topline safety, tolerability, and pharmacodynamic data from the multicenter LOTUS Part 1 clinical trial of EB-105 in patients
read more
Dr. Abbey Presented National Webinar on Treatment of Patients with Diabetic Macular Edema and 20/50 or Worse Vision
On Monday, September 19, 2022, Texas Retina Associates’ Ashkan M. Abbey, MD, delivered a webinar titled, “Does Treatment Selection Matter in Patients with Diabetic Macular Edema and 20/50 or Worse Vision?” Dr. Abbey discussed
read more Dr. Abbey Presented Preliminary Findings of a Diabetic Macular Edema Clinical Trial at the Retina World Congress
Texas Retina Associates’ Ashkan M. Abbey, MD served as an invited faculty member for the Retina World Congress held May 12-15, 2022, in Fort Lauderdale, Florida. This global physician meeting featured presentations
read more
Dr. Kothari and Dr. Abbey Earn “Top 10 Poster Award” at American Society of Retina Specialists 2021 Annual Scientific Meeting
A research poster by Texas Retina Associates physicians Nikisha Kothari, MD, and Ashkan M. Abbey, MD, was awarded “Top 10” honors at the American Society of Retina Specialists (ASRS) 2021 Annual Scientific
read more